title: Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials.
abstract: Malignant pleural mesothelioma (MPM) is a hard to treat malignancy arising from the mesothelial surface of the pleura. Immune checkpoint inhibitors are considered a promising therapeutic strategy in many hardto- treat malignancies. In this review, we are trying to provide an in depth coverage of the prognostic value of immune checkpoints aberrations as well as discuss the different novel therapeutic strategies implementing these agents in the management of MPM.
authors.affiliation: Faculty of Medicine, Ain Shams University, Cairo. Egypt.
authors.forename: Hadeer
authors.initials: H
authors.lastname: Mohamed
authors.affiliation: Faculty of Medicine, Ain Shams University, Cairo. Egypt.
authors.forename: Mostafa
authors.initials: M
authors.lastname: Eltobgy
authors.affiliation: Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo. Egypt.
authors.forename: Omar
authors.initials: O
authors.lastname: Abdel-Rahman
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D055633:Immune System Phenomena / Q000187:drug effects; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D008654:Mesothelioma / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D000086002:Mesothelioma, Malignant; D010997:Pleural Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D013329:Structure-Activity Relationship
chemical_list: D000970:Antineoplastic Agents
keywords: Mesothelioma; immune; ipilimumab; pembrolizumab; prognostic value.; tremelimumab